Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance

被引:53
作者
Boichuk, Sergei [1 ]
Galembikova, Aigul [1 ]
Sitenkov, Alexandr [1 ]
Khusnutdinov, Ramil [1 ]
Dunaev, Pavel [1 ]
Valeeva, Elena [1 ]
Usolova, Natalia [1 ]
机构
[1] Kazan State Med Univ, Dept Pathol, 49 Butlerov St, Kazan 420012, Russia
基金
俄罗斯科学基金会;
关键词
triple negative basal-like breast cancer; apoptosis; chemoresistance; paclitaxel; P-glycoprotein; TAXOL; TRIAL; DOXORUBICIN; PACLITAXEL; FEATURES; AGENT; GENE; DRUG;
D O I
10.3892/ol.2017.6795
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Triple-negative breast carcinoma (TNBC) is one of the most aggressive subtypes of breast cancer and is associated with an unfavorable prognosis. The management of TNBC is currently based on the use of classical cytotoxic drugs, i.e., anthracyclines and/or microtubule-binding agents (TBAs). However, conventional chemotherapy is not always effective in these tumors and a systemic relapse is often observed, potentially due to the development of multi-drug resistance (MDR). Therefore, an improved understanding of MDR mechanisms may improve the therapeutic strategies for TNBC. In the present study, a paclitaxel-resistant (TxR) breast cancer cell subline of HCC1806 TNBC cells was established and characterized. The resistance index of this subline was calculated according to the IC50 of HCC1806-TxR relative to the parental HCC1806 cells (16.86-fold). TxR-cells also exhibited cross-resistance to vinblastin, doxorubicin and etoposide (similar to 14-, similar to 4-and similar to 3-fold, respectively). As assessed with reverse transcription-quantitative polymerase chain reaction, TxR-resistant cells exhibited the upregulated expression of a number of multidrug resistance-associated genes, including MDR-1, MRP-1, -5, -6 and YB-1. The TxR cells also exhibited an increased expression of MDR-related proteins including MDR1 and MRP-1, which led to a substantial increase (5.4-fold) of the paclitaxel efflux from TxR-cells. In addition, the pro-apoptotic protein Fas was downregulated, whereas the anti-apoptotic Bcl-2 was upregulated, in TxR-cells. This may explain why a reduced extent of apoptosis was observed when TxR cells were exposed to TBAs and topoisomerase type II inhibitors, relative to the parental HCC1806 cells. Thus, the HCC1806-TxR cell line may serve as an appropriate model for the analysis of chemoresistance mechanisms in TNBCs, and for the investigation of novel anticancer agents for overcoming MDR-mediated mechanisms in TNBC.
引用
收藏
页码:5039 / 5045
页数:7
相关论文
共 24 条
[1]
Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research [J].
Bosch, Ana ;
Eroles, Pilar ;
Zaragoza, Rosa ;
Vina, Juan R. ;
Lluch, Ana .
CANCER TREATMENT REVIEWS, 2010, 36 (03) :206-215
[2]
A PHASE-I TRIAL OF TAXOL GIVEN BY A 6-HOUR INTRAVENOUS-INFUSION [J].
BROWN, T ;
HAVLIN, K ;
WEISS, G ;
CAGNOLA, J ;
KOELLER, J ;
KUHN, J ;
RIZZO, J ;
CRAIG, J ;
PHILLIPS, J ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1261-1267
[3]
Triple-negative breast cancer: Clinical features and patterns of recurrence [J].
Dent, Rebecca ;
Trudeau, Maureen ;
Pritchard, Kathleen I. ;
Hanna, Wedad M. ;
Kahn, Harriet K. ;
Sawka, Carol A. ;
Lickley, Lavina A. ;
Rawlinson, Ellen ;
Sun, Ping ;
Narod, Steven A. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434
[4]
Microtubule-binding agents: a dynamic field of cancer therapeutics [J].
Dumontet, Charles ;
Jordan, Mary Ann .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) :790-803
[5]
FUCHS DA, 1978, CANCER TREAT REP, V62, P1219
[6]
Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure [J].
Guo, BQ ;
Villeneuve, DJ ;
Hembruff, SL ;
Kirwan, AF ;
Blais, DE ;
Bonin, M ;
Parissenti, AM .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 85 (01) :31-51
[7]
INACTIVATION OF BCL-2 BY PHOSPHORYLATION [J].
HALDAR, S ;
JENA, N ;
CROCE, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (10) :4507-4511
[8]
ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer [J].
Hasanabady, Maryam Hosseini ;
Kalalinia, Fatemeh .
JOURNAL OF BIOSCIENCES, 2016, 41 (02) :313-324
[9]
PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER [J].
HOLMES, FA ;
WALTERS, RS ;
THERIAULT, RL ;
FORMAN, AD ;
NEWTON, LK ;
RABER, MN ;
BUZDAR, AU ;
FRYE, DK ;
HORTOBAGYI, GN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) :1797-1805
[10]
Microtubules as a target for anticancer drugs [J].
Jordan, MA ;
Wilson, L .
NATURE REVIEWS CANCER, 2004, 4 (04) :253-265